MSA-P
MCID: MLT116
MIFTS: 29

Multiple System Atrophy, Parkinsonian Type (MSA-P)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple System Atrophy, Parkinsonian Type

MalaCards integrated aliases for Multiple System Atrophy, Parkinsonian Type:

Name: Multiple System Atrophy, Parkinsonian Type 58
Msa, Parkinsonian Type 58
Msa-P 58

Characteristics:

Orphanet epidemiological data:

58
multiple system atrophy, parkinsonian type
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Multiple System Atrophy, Parkinsonian Type

MalaCards based summary : Multiple System Atrophy, Parkinsonian Type, also known as msa, parkinsonian type, is related to multiple system atrophy 1 and supranuclear palsy, progressive, 1. An important gene associated with Multiple System Atrophy, Parkinsonian Type is COQ2 (Coenzyme Q2, Polyprenyltransferase). The drugs Rasagiline and Neuroprotective Agents have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and cortex, and related phenotypes are abnormal pyramidal sign and depressivity

Related Diseases for Multiple System Atrophy, Parkinsonian Type

Diseases related to Multiple System Atrophy, Parkinsonian Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 10.5
2 supranuclear palsy, progressive, 1 10.3
3 aspiration pneumonia 10.1
4 stuttering 10.1
5 parkinsonism 10.1
6 autonomic dysfunction 10.1
7 ataxia and polyneuropathy, adult-onset 10.1
8 autosomal dominant cerebellar ataxia 9.9
9 constipation 9.9
10 dystonia 9.9
11 pathologic nystagmus 9.9
12 corticobasal degeneration 9.9
13 pure autonomic failure 9.9
14 dysautonomia 9.9
15 spinocerebellar degeneration 9.9

Graphical network of the top 20 diseases related to Multiple System Atrophy, Parkinsonian Type:



Diseases related to Multiple System Atrophy, Parkinsonian Type

Symptoms & Phenotypes for Multiple System Atrophy, Parkinsonian Type

Human phenotypes related to Multiple System Atrophy, Parkinsonian Type:

58 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal pyramidal sign 58 31 frequent (33%) Frequent (79-30%) HP:0007256
2 depressivity 58 31 frequent (33%) Frequent (79-30%) HP:0000716
3 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
4 anxiety 58 31 frequent (33%) Frequent (79-30%) HP:0000739
5 rigidity 58 31 frequent (33%) Frequent (79-30%) HP:0002063
6 stridor 58 31 frequent (33%) Frequent (79-30%) HP:0010307
7 apathy 58 31 frequent (33%) Frequent (79-30%) HP:0000741
8 axial dystonia 58 31 frequent (33%) Frequent (79-30%) HP:0002530
9 frequent falls 58 31 frequent (33%) Frequent (79-30%) HP:0002359
10 orthostatic hypotension due to autonomic dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0004926
11 raynaud phenomenon 58 31 frequent (33%) Frequent (79-30%) HP:0030880
12 postural instability 58 31 frequent (33%) Frequent (79-30%) HP:0002172
13 abnormal rapid eye movement sleep 58 31 frequent (33%) Frequent (79-30%) HP:0002494
14 parkinsonism 58 31 frequent (33%) Frequent (79-30%) HP:0001300
15 orofacial dyskinesia 58 31 frequent (33%) Frequent (79-30%) HP:0002310
16 bradykinesia 58 31 frequent (33%) Frequent (79-30%) HP:0002067
17 central sleep apnea 58 31 frequent (33%) Frequent (79-30%) HP:0010536
18 resting tremor 58 31 frequent (33%) Frequent (79-30%) HP:0002322
19 autonomic erectile dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0008652
20 autonomic bladder dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0005341
21 abnormal brain fdg positron emission tomography 58 31 frequent (33%) Frequent (79-30%) HP:0012658
22 orthostatic syncope 58 31 frequent (33%) Frequent (79-30%) HP:0012670
23 female anorgasmia 58 31 frequent (33%) Frequent (79-30%) HP:0030015
24 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
25 gait ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002066
26 progressive cerebellar ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002073
27 postural tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0002174
28 gaze-evoked nystagmus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000640
29 camptocormia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100595
30 dysautonomia 58 Frequent (79-30%)

Drugs & Therapeutics for Multiple System Atrophy, Parkinsonian Type

Drugs for Multiple System Atrophy, Parkinsonian Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 2 136236-51-6 3052776
2 Neuroprotective Agents Phase 2
3 Protective Agents Phase 2
4 Monoamine Oxidase Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed NCT00977665 Phase 2 rasagiline mesylate;placebo
2 Pathogenesis and Diagnosis of Multiple System Atrophy (MSA): PET Study of Neurochemical and Autonomic Disorders in MSA Completed NCT02035761

Search NIH Clinical Center for Multiple System Atrophy, Parkinsonian Type

Genetic Tests for Multiple System Atrophy, Parkinsonian Type

Anatomical Context for Multiple System Atrophy, Parkinsonian Type

MalaCards organs/tissues related to Multiple System Atrophy, Parkinsonian Type:

40
Eye, Brain, Cortex, Cerebellum, Thalamus, Subthalamic Nucleus, Pons

Publications for Multiple System Atrophy, Parkinsonian Type

Articles related to Multiple System Atrophy, Parkinsonian Type:

(show top 50) (show all 471)
# Title Authors PMID Year
1
A study on the characteristics of cognitive function in patients with multiple system atrophy in China. 61
33654145 2021
2
Pathological laughter and crying in multiple system atrophy with different subtypes: Frequency and related factors. 61
33517229 2021
3
Diagnostic usefulness of putaminal abnormality on diffusion- and susceptibility-weighted imaging: two illustrative cases of multiple system atrophy-parkinsonian type. 61
33025326 2021
4
Sympathetic and sensory nerve fiber function in multiple system atrophy and idiopathic Parkinson's disease. 61
33715046 2021
5
Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. 61
33713904 2021
6
Interrelationships between Survival, Sex, and Blood Pressure in Patients with Multiple System Atrophy. 61
33601380 2021
7
Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 years. 61
33558361 2021
8
Sighs during sleep in multiple system atrophy. 61
33401147 2021
9
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. 61
33557920 2021
10
Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features. 61
32963152 2021
11
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting. 61
33137232 2021
12
"Hot cross bun" is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. 61
33589630 2021
13
Atypical parkinsonian syndromes in a North African tertiary referral center. 61
33179436 2021
14
Mini-Review: The MSA transcriptome. 61
33352281 2021
15
Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. 61
33492245 2021
16
The Value of Sacral Reflex and Sympathetic Skin Reflex in the Diagnosis of Multiple System Atrophy P-Type. 61
33552462 2021
17
Morphology and signal changes of the lentiform nucleus based on susceptibility weighted imaging in parkinsonism-predominant multiple system atrophy. 61
33189038 2020
18
The Profile and Evolution of Neuropsychiatric Symptoms in Multiple System Atrophy: Self- and Caregiver Report. 61
33261525 2020
19
Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy. 61
32940411 2020
20
Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity. 61
33234871 2020
21
Magnetic sphincter augmentation is an effective treatment for atypical symptoms caused by gastroesophageal reflux disease. 61
31792691 2020
22
[Abnormalities of white matter differentiate the Parkinson variant of multiple system atrophy from Parkinson's disease]. 61
33120491 2020
23
The secondary structural difference between Lewy body and glial cytoplasmic inclusion in autopsy brain with synchrotron FTIR micro-spectroscopy. 61
33173082 2020
24
Measurement of outflow resistance imposed by magnetic sphincter augmentation: defining normal values and clinical implication. 61
33051761 2020
25
Regression of Barrett's esophagus after magnetic sphincter augmentation: intermediate-term results. 61
33033913 2020
26
Orofacial dystonia and asssociated bulbar symptoms in multiple system atrophy: A blinded video analysis. 61
32622521 2020
27
Multiple System Atrophy - Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder. 61
33173654 2020
28
Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. 61
32557839 2020
29
Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. 61
32978422 2020
30
Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. 61
32698058 2020
31
Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival. 61
32320519 2020
32
Neuropathological findings in multiple system atrophy with cognitive impairment. 61
32367182 2020
33
Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. 61
32493431 2020
34
Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation. 61
32415621 2020
35
Neurogenic lower urinary tract dysfunction predicts prognosis in patients with multiple system atrophy. 61
32166422 2020
36
Transcriptomic differences in MSA clinical variants. 61
32587362 2020
37
Parkinsonian and Cerebellar Phenotypes of Probable MSA: An Insight in to Prognostic Factors Based on Autonomic Functions. 61
32606514 2020
38
Serum adiponectin levels between patients with Parkinson's disease and those with PSP. 61
31897945 2020
39
Pathological changes in the cerebellum of patients with multiple system atrophy and Parkinson's disease-a stereological study. 61
31769073 2020
40
Is There a Difference in Autonomic Dysfunction Between Multiple System Atrophy Subtypes? 61
32373657 2020
41
[Diagnosis of MSA-P and PSP-P in Early Stage]. 61
32284458 2020
42
Progression of Oropharyngeal Dysphagia in Patients with Multiple System Atrophy. 61
30852647 2020
43
Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy. 61
31865188 2020
44
Gray Matter Atrophy in Parkinson's Disease and the Parkinsonian Variant of Multiple System Atrophy: A Combined ROI- and Voxel-Based Morphometric Study. 61
32555945 2020
45
Voxel-Based Meta-Analysis of Gray Matter Abnormalities in Multiple System Atrophy. 61
33328969 2020
46
Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant. 61
31559533 2020
47
MRI-Based Radiomics of Basal Nuclei in Differentiating Idiopathic Parkinson's Disease From Parkinsonian Variants of Multiple System Atrophy: A Susceptibility-Weighted Imaging Study. 61
33281598 2020
48
Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study. 61
32089817 2020
49
Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy. 61
31707374 2020
50
Vocal cord electromyographic correlates of stridor in multiple system atrophy phenotypes. 61
31809947 2020

Variations for Multiple System Atrophy, Parkinsonian Type

Expression for Multiple System Atrophy, Parkinsonian Type

Search GEO for disease gene expression data for Multiple System Atrophy, Parkinsonian Type.

Pathways for Multiple System Atrophy, Parkinsonian Type

GO Terms for Multiple System Atrophy, Parkinsonian Type

Sources for Multiple System Atrophy, Parkinsonian Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....